Haisco Pharmaceutical Group Co., Ltd. (China)

Efficacy and Safety of Crisugabalin for Inadequately Controlled Diabetic Peripheral Neuropathic Pain: A Randomized, Active‐Controlled, Phase 2 Trial

AIMS: Crisugabalin (HSK16149), a selective γ-aminobutyric acid (GABA) analog, has shown preliminary efficacy in controlling diabetic peripheral neuropathic pain (DPNP), but efficacy in patients with inadequate response to prior pregabalin treatment remains unknown. MATERIALS AND...